Risultati per: Lo stress può essere causa di infarto ed ictus

Studio, già una perdita peso del 3% migliora controllo diabete

La Conferenza Stato-Regioni ha approvato l’intesa che sancisce il via libera alla nuova campagna di immunizzazione

Primo studio in Italia con l’arruolamento di 60 pazienti

Primo studio in Italia con l’arruolamento di 60 pazienti

US Surgeon General Vivek Murthy, MD, MBA, issued an advisory on the mental health and well-being of parents and caregivers of children younger than 18 years. The report comes in response to the intense pressure reported by the roughly 63 million parents of children in the US: 33% reported high levels of stress over the course of a month compared with 20% of other adults in 2023.

Studio: è utile non solo per prevenire. Ma attenti agli infortuni

Il 19 ottobre castello Aymavilles colorato per Giornata afasia

Dati Ipsos e Fondazione Paoletti

Sip, incidono anche i pregiudizi, la discriminazione e le molestie

Sip,incidono anche i pregiudizi,la discriminazione e le molestie

Cardiologia, al via ad Ancona guidato da professor Dello Russo

I risultati del progetto Iss “Veterani in Sella”

I risultati del progetto Iss “Veterani in Sella”

Al via la campagna “Ridefinirlo”. In Ue uno su 2 ignorai rischi

Introduction
The use and value of artificial intelligence (AI)-driven tools and techniques are under investigation in detecting coronary artery disease (CAD). EchoGo Pro is a patented AI-driven stress echocardiography analysis system produced by Ultromics Ltd. (henceforth Ultromics) to support clinicians in detecting cardiac ischaemia and potential CAD. This manuscript presents the research protocol for a field study to independently evaluate the accuracy, acceptability, implementation barriers, users’ experience and willingness to pay, cost-effectiveness and value of EchoGo Pro.

Methods and analysis
The ‘Evaluating AI-driven stress echocardiography analysis system’ (EASE) study is a mixed-method evaluation, which will be conducted in five work packages (WPs). In WP1, we will examine the diagnostic accuracy by comparing test reports generated by EchoGo Pro and three manual raters. In WP2, we will focus on interviewing clinicians, innovation/transformation staff, and patients within the National Health Service (NHS), and staff within Ultromics, to assess the acceptability of this technology. In this WP, we will determine convergence and divergence between EchoGo Pro recommendations and cardiologists’ interpretations and will assess what profile of cases is linked with convergence and divergence between EchoGo Pro recommendations and cardiologists’ interpretations and how these link to outcomes. In WP4, we will conduct a quantitative cross-sectional survey of trust in AI tools applied to cardiac care settings among clinicians, healthcare commissioners and the general public. Lastly, in WP5, we will estimate the cost of deploying the EchoGo Pro technology, cost-effectiveness and willingness to pay cardiologists, healthcare commissioners and the general public. The results of this evaluation will support evidence-informed decision-making around the widespread adoption of EchoGo Pro and similar technologies in the NHS and other health systems.

Ethics approval and dissemination
This research has been approved by the NHS Health Research Authority (IRAS No: 315284) and the London South Bank University Ethics Panel (ETH2223-0164). Alongside journal publications, we will disseminate study methods and findings in conferences, seminars and social media. We will produce additional outputs in appropriate forms, for example, research summaries and policy briefs, for diverse audiences in NHS.